Suppr超能文献

印度私立部门的耐多药结核病治疗:孟买一家三级转诊私立医院的结果

Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai.

作者信息

Udwadia Zarir F, Moharil Gautam

机构信息

Department of Pulmonology, Hinduja Hospital and Research Center, Mumbai, Maharashtra, India.

出版信息

Lung India. 2014 Oct;31(4):336-41. doi: 10.4103/0970-2113.142101.

Abstract

BACKGROUND

There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a private tertiary referral institute.

MATERIALS AND METHODS

A prospective analysis of a cohort of MDR-TB patients treated in a tertiary private hospital, with the back-up of a Level 2 mycobacterial laboratory, which has recently received recognition by the Revised National Tuberculosis Control Program (RNTCP) for second-line drug susceptibility (DST). All patients received an individualized MDR regimen on an ambulatory basis.

RESULTS

Our 68% success rates are respectable and show that given the right laboratory backing, MDR-TB can be managed successfully in selected private practice settings.

摘要

背景

关于在直接观察治疗短程化疗强化项目(DOTS plus)之外接受私人治疗的耐多药结核病(MDR-TB)患者的经验和治疗结果的数据非常有限。本研究的目的是提供在一家私立三级转诊机构接受治疗的MDR-TB患者前瞻性队列的特征和治疗结果。

材料与方法

对在一家私立三级医院接受治疗的MDR-TB患者队列进行前瞻性分析,该医院有一家二级分枝杆菌实验室提供支持,该实验室最近已获得修订后的国家结核病控制项目(RNTCP)对二线药物敏感性试验(DST)的认可。所有患者均在门诊接受个体化的MDR治疗方案。

结果

我们68%的成功率是可观的,这表明在有合适的实验室支持的情况下,MDR-TB在选定的私人医疗机构中可以得到成功管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9475/4220314/896370a92754/LI-31-336-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验